CCM
PTCT icon

Consonance Capital Management’s PTC Therapeutics PTCT Stock Holding History

Consonance Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,946,009
Closed -$79M – 26
2017
Q3 		$79M Hold
3,946,009
– – 8.73% 4
2017
Q2 		$72.3M Buy
+3,946,009
New +$53.2M 8.52% 5

Other funds holding PTCT

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

Consonance Capital Management's PTCT Position: Q4 2017 in Review

Consonance Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2017, closing a stake of 3,946,009 shares — an estimated $79M sold.

Consonance Capital Management first reported a position in PTCT in Q2 2017 and held it in 2 quarters. The position peaked at $79M in Q3 2017. 125 funds tracked by Wall St. Rank hold PTCT as of Q4 2017.

  • Consonance Capital Management reported no remaining PTC Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Consonance Capital Management sold 3,946,009 PTC Therapeutics shares in Q4 2017, an estimated $79M.
  • Consonance Capital Management first reported a position in PTC Therapeutics in Q2 2017 and held it in 2 quarters.
  • Consonance Capital Management's PTC Therapeutics position peaked at $79M in Q3 2017.
  • 125 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2017.

Based on Consonance Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.